Jonathon B. Cohen, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, provides an overview of the current treatment landscape for relapsed mantle-cell lymphoma (MCL) including the use of BTK inhibitors which are effective in relapsed patients but do not induce long-term remission. Dr Cohen also discusses the use of lenalidomide and venetoclax in this indication, as well as CAR T-cell therapies approved for relapsed MCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть